Effectivity and Safety Profile of Tenapanor, a Sodium-Hydrogen Exchanger Isoform 3 Inhibitor, as an Innovative Treatment for Hyperphosphatemia in Chronic Kidney Disease, a Systematic Review of Clinical Studies

William Suciangto, Haerani Rasyid, Anastasya Angelica Vicente, Winny Suciangto
doi: https://doi.org/10.1101/2023.12.19.23300205

Data Availability

All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript

Back to top
Posted December 19, 2023.
Download PDF
Data/Code
Email
Effectivity and Safety Profile of Tenapanor, a Sodium-Hydrogen Exchanger Isoform 3 Inhibitor, as an Innovative Treatment for Hyperphosphatemia in Chronic Kidney Disease, a Systematic Review of Clinical Studies
William Suciangto, Haerani Rasyid, Anastasya Angelica Vicente, Winny Suciangto
medRxiv 2023.12.19.23300205; doi: https://doi.org/10.1101/2023.12.19.23300205
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area